Wappler-Guzzetta Edina A, Shafiq Asad, Asad Umaima, Chakravarty Tushar, Nedelcu Elena G
Department of Laboratory Medicine, University of California San Francisco, San Francisco, CA, United States.
College of Business and Economics, California State University Fullerton, Fullerton, CA, United States.
Am J Clin Pathol. 2025 Oct 4;164(4):626-633. doi: 10.1093/ajcp/aqaf093.
Prior studies have shown that pretransfusion medication is not effective in preventing allergic transfusion reactions (ATRs), but these studies did not consider the patient's history of ATR. This study evaluated whether pretransfusion antiallergy medications decrease the chance of ATRs in patients with a history of severe ATR.
This single-center, retrospective study investigated the effect of pretransfusion medications on preventing ATRs in patients with a history of at least 1 severe ATR between March 2018 and January 2024. Patient demographics as well as clinical and transfusion reaction data were collected from our electronic health record (EHR) system. Data were analyzed using SPSS (IBM Corp) and machine learning in Python, version 3.12.4.
In our cohort, 53 patients aged 5 weeks to 94 years with 2767 analyzable transfusion encounters had experienced 88 lifelong mild and severe ATRs. Premedication (P = .021), regular antiallergy medication (P < .001), and washing/volume reduction (P = .032) were associated with a statistically significantly lower chance of developing ATRs in our patient population.
Patients with at least 1 severe ATR benefit from pretransfusion administration of antiallergy medications.
先前的研究表明,输血前用药在预防过敏输血反应(ATR)方面无效,但这些研究未考虑患者的ATR病史。本研究评估了输血前抗过敏药物是否能降低有严重ATR病史患者发生ATR的几率。
这项单中心回顾性研究调查了2018年3月至2024年1月期间输血前用药对至少有1次严重ATR病史患者预防ATR的效果。从我们的电子健康记录(EHR)系统收集患者人口统计学以及临床和输血反应数据。使用SPSS(IBM公司)和Python 3.12.4版本中的机器学习对数据进行分析。
在我们的队列中,53例年龄在5周至94岁之间、有2767次可分析输血经历的患者发生了88次终身轻度和重度ATR。在我们的患者群体中,预处理(P = 0.021)、常规抗过敏药物(P < 0.001)和洗涤/减少容量(P = 0.032)与发生ATR的几率在统计学上显著降低相关。
至少有1次严重ATR的患者可从输血前给予抗过敏药物中获益。